Jasper Therapeutics Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z
Jasper Therapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for GFF MDI (PT 003) in Chronic Obstructive Pulmonary Disease (COPD) (Phase 3).
| Asset | Indication | Modality | Stage | Public Note |
|---|---|---|---|---|
| Who We Are | targeting mast cells to treat chronic mast cell diseases | n/a | n/a | Public pipeline row |
| CD117 | developing briquilimab as a therapeutic for chronic mast cell diseases | Monoclonal Antibody | n/a | Public pipeline row |
| Harry Malech, M.D. | n/a | Gene Therapy | n/a | Public pipeline row |
| GFF MDI (PT 003) | Chronic Obstructive Pulmonary Disease (COPD) | n/a | Phase 3 | Public pipeline row |
| Humanized anti-CD117 Monoclonal Antibody (JSP191) | MYELODYSPLASTIC SYNDROME; MDS | ACUTE MYELOID LEUKEMIA; AML | Antibody | Phase 1 | Public pipeline row |
| The ReGelTec HYDRAFIL™ System | Degenerative Disc Disease (DDD) | n/a | Na | Public pipeline row |
| Revefenacin | Chronic Obstructive Pulmonary Disease | n/a | Phase4 | Public pipeline row |
| GFF MDI (PT003) | Chronic Obstructive Pulmonary Disease | n/a | Phase 3 | Public pipeline row |
Estimated cash runway: Runway < 6 months.
This is an automated estimate and may differ from company guidance.
| NCT ID | Phase | Status | Enrollment | Primary Completion |
|---|---|---|---|---|
| NCT01970878 | Phase 3 | COMPLETED | 892 | 2015-03 |
| NCT02343458 | Phase 3 | COMPLETED | 1756 | 2017-08-31 |
| NCT04429191 | Phase 1 | UNKNOWN | 40 | 2023-10-15 |
| NCT05165485 | Phase4 | COMPLETED | 404 | 2023-11-13 |
| NCT06011551 | Na | RECRUITING | 225 | 2027-11 |
Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.
Get the weekly biotech catalyst watchlistThis page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.